Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomesDescription
While metformin remains the first line treatment in most cases, choices for second line treatment now extend beyond sulfonylureas and include the sodium–glucose cotransporter 2 (SGLT2) inhibitors, glucagon‐like peptide 1 (GLP1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors.
- Explain key components of the review.
- List main recommendations.
- Recognise changes in management as a result of the review.
Authors: Renata Libianto, Timothy ME Davis, Elif I Ekinci
Article Type: Narrative review